Seroatlas · Human Serome Atlas

BLVRB

Flavin reductase (NADPH)

Also known as: BLVRB_HUMAN, FLR, SDR43U1

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: P30043
Gene: BLVRB
Ensembl: ENSG00000090013
Chromosome: 19
Canonical length: 206 aa
Protein class: Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins
Subcellular location: Nucleoplasm,Vesicles,Plasma membrane,Cytosol

OverviewNCBI Gene

Enables biliverdin reductase [NAD(P)+] activity; peptidyl-cysteine S-nitrosylase activity; and riboflavin reductase (NADPH) activity. Involved in heme catabolic process; megakaryocyte differentiation; and negative regulation of insulin receptor signaling pathway. Located in cytosol; nucleoplasm; and plasma membrane. Is active in cytoplasm. [provided by Alliance of Genome Resources, Apr 2025]

Canonical amino-acid sequenceUniProt

206 residues, UniProt reviewed canonical sequence.

>P30043|BLVRB
     1  MAVKKIAIFG ATGQTGLTTL AQAVQAGYEV TVLVRDSSRL PSEGPRPAHV VVGDVLQAAD
    61  VDKTVAGQDA VIVLLGTRND LSPTTVMSEG ARNIVAAMKA HGVDKVVACT SAFLLWDPTK
   121  VPPRLQAVTD DHIRMHKVLR ESGLKYVAVM PPHIGDQPLT GAYTVTLDGR GPSRVISKHD
   181  LGHFMLRCLT TDEYDGHSTY PSHQYQ

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against BLVRB can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.26
Highest tissue expression: 589 nTPM

Expression across tissuesHPA

Tissue

bone marrow: 589 nTPM
liver: 279 nTPM
skeletal muscle: 214 nTPM
esophagus: 198 nTPM
spleen: 175 nTPM
stomach: 142 nTPM

Single-cell type

esophageal apical cells: 3,709 nCPM
hofbauer cells: 2,026 nCPM
erythrocyte progenitors: 1,710 nCPM
enterocytes: 925 nCPM
erythrocytes: 922 nCPM
kupffer cells: 873 nCPM

Immune cell

classical monocyte: 466 nTPM
myeloid DC: 344 nTPM
total PBMC: 260 nTPM
intermediate monocyte: 221 nTPM
non-classical monocyte: 118 nTPM
plasmacytoid DC: 76 nTPM

Brain region

pons: 56 nTPM
medulla oblongata: 48 nTPM
white matter: 46 nTPM
thalamus: 44 nTPM
choroid plexus: 43 nTPM
spinal cord: 39 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.76
gnomAD pLI: 0
gnomAD missense Z: 0.45
DepMap mean gene effect: 0.01
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

biliverdin reductase [NAD(P)H] activity
peptidyl-cysteine S-nitrosylase activity
FMN reductase (NADH) activity
FMN reductase (NADPH) activity
riboflavin reductase (NADPH) activity

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads BLVRB as an antibody target. Whether an autoantibody or antibody against BLVRB could matter depends on whether native BLVRB is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

BLVRB is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label BLVRB as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...